BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22

• Press Releases

  Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

  December 22, 2025

   · 

  7 min read
• Press Releases

  Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

  December 22, 2025

   · 

  3 min read
• Press Releases

  Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

  December 22, 2025

   · 

  8 min read
• Press Releases

  BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

  December 22, 2025

   · 

  23 min read
• Press Releases

  Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

  December 22, 2025

   · 

  6 min read
• Press Releases

  IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

  December 22, 2025

   · 

  6 min read
• Press Releases

  Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

  December 22, 2025

   · 

  4 min read
• Press Releases

  Cue Biopharma Announces Pricing of $10 Million Public Offering

  December 22, 2025

   · 

  5 min read
• Press Releases

  Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 19, 2025

  December 22, 2025

   · 

  1 min read
• Press Releases

  European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

  December 22, 2025

   · 

  14 min read